Press Release December 10, 2021

Adicet Bio Closes $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

The Life Sciences team advised Adicet Bio, Inc. (Nasdaq: ACET) on its underwritten public offering of 7,187,500 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a public offering price of $14 per share, less underwriting discounts and commissions. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $100.6 million.

Adicet is a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases.

The Goodwin team was led by Danielle Lauzon, Gaby Morales-Rivera, Jason Goldfarb, and Kathryn Witham.

For more details, read the press release.